Federated Hermes, Inc. Liquidia Corp Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$11.35 - $16.73 $1.83 Million - $2.7 Million	161,617 New	161,617 $2.38 Million
Q3 2023 Nov 13, 2023	BUY	$6.27 - $8.15 $20,446 - $26,577	3,261 Added 4592.96%	3,332 $21,000
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $470 - $702	71 New	71 $0
Q3 2020 Nov 12, 2020	SELL	$4.34 - $8.28 $113,126 - $215,826	-26,066 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.86 - $11.44 $126,680 - $298,195	26,066 New	26,066 $219,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.